Radiopharmaceutical Market Scenario:
As the healthcare industry is moving towards the personalized approaches, the role of radiopharmaceutical is also increasing. The radiopharmaceutical is acting as an all-rounder radiopharmaceutical from diagnosis to treatment for various chronic diseases such as cancers and other neurological disorders, which has provided an impetus to the market. Demand for radiopharmaceuticals is growing due to raising awareness about availability of radiation and radioisotopes in medicine, particularly for diagnosis and therapy for various chronic conditions. In developed countries about one person in 50 uses diagnostic nuclear medicine every year, and the demand for therapy with radioisotopes is about one-tenth of this. Radiopharmaceuticals use radiation to provide diagnostic information about the functioning of a person’s specific organs while radiotherapy can be used to treat some medical conditions, especially cancer, used to weaken or destroy particular targeted cells. The global radiopharmaceutical market is expected to grow at a CAGR of 8.7% during the forecast period 2017–2023.
Avail Exclusive Sample Copy of Radiopharmaceutical Market spread across 271 Premium Pages, 10+ and Supported with Full TOC, is Available @ https://www.marketresearchfuture.com/sample_request/1650
Some of the key players in this market are Jubilant Life Sciences Ltd., Siemens AG, Sun Pharmaceutical Industries Ltd., Bayer AG, Cardinal Health Inc., Medtronic, General Electric Company (GE Healthcare) and more.
The global radiopharmaceutical market is segmented based on type, type of test, application, route of administration, and end user.
By type, the market for radiopharmaceutical is segmented into diagnostic type radiopharmaceuticals and therapeutic type radiopharmaceuticals. The diagnostic type radiopharmaceutical segment is further sub-segmented into SPECT radiopharmaceutical and PET radiopharmaceutical. The therapeutic type radiopharmaceutical segment is further sub-segmented into beta emitters, alpha emitters, brachytherapy. The SPECT radiopharmaceutical segment is further sub-segmented into Technetium-99m, Thallium-201, Iodine-123, and others. The PET radiopharmaceutical segment is further sub-segmented into F-18, Rubidium-82, and others. The Beta emitters segment is further sub-segmented into Iodine-131, Yttrium-90, Samarium-153, Rhenium-186, Lutetium-177, and others. The brachytherapy segment is sub-segmented into Iodine-125, Iridium-192, Cesium-131, and others.
By type of test, the market is segmented into myocardial perfusion scan, lung scan, bone scan, white blood cell scan, gallium scan, renal nuclear medicine scan, parathyroid scans, hepatobiliary scans, cerebral perfusion scan and others. The bone scan segment is further sub-segmented into Technetium-99m 1st, fluoride-18 2nd, and others. The Myocardial Perfusion Scan segment is further sub-segmented into Technetium-99m, Thallium-201, Rubidium-82, and others. The lung scan segment is further sub-segmented into Xenon-133, Krypton-81m, and others. The White blood cell Scan segment is sub-segmented into Indium-111 and others.
Ask any Queries to Experts about Niche Segments, Requires Regional Data and Top Players @ https://www.marketresearchfuture.com/enquiry/1650
The global radiopharmaceutical market is segmented into four major regions including Americas, Europe, Asia Pacific and the Middle East & Africa. Among these, Americas and Europe will continue to present lucrative growth opportunities for market players during the forecast period. Currently, these two regions collectively account for the largest share of the market and the trend is likely to continue over the next couple of years. Higher healthcare spending and existence a robust healthcare system system in these regions is reflecting favorably on the market. In Asia Pacific, increased focus on improving the quality of healthcare services is auguring well for market players operating in the region. During the review period, the market in the region is expected to capture a strong CAGR.
Major TOC of Radiopharmaceutical Market Research Report – Forecast to 2023:
1 Report Prologue
2 Executive Summary
3 Market Introduction
4 Research Methodology
5 Market Dynamics
6 Market Factor Analysis
7 Global Radiopharmaceutical Market, by Type
8 Global Radiopharmaceuticals Market, by Type of Test
9 Global Radiopharmaceutical Market, by Application
10 Global Radiopharmaceutical Market, by Route of Administration
11 Global Radiopharmaceutical Market, by End-User
12 Global Radiopharmaceutical Market, by Region
13 Competitive Landscape
14 Company Profile
Essential points covered in Global Radiopharmaceutical Market 2018 to 2023:-
What will the market size and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Avail Dazzling Discount @https://www.marketresearchfuture.com/sample_request/1650
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar